Antihypertensive Drugs Market by Drug Class – Angiotensin II Receptor Blockers (ARBs), Angiotensin-converting Enzyme (ACE) Inhibitors, β-blockers, Calcium Channel Blockers (CCBs), Diuretics, Fixed-dose Combinations (FDCs), Others and Forecast 2017-2021

Antihypertensive Drugs Market by Drug Class – Angiotensin II Receptor Blockers (ARBs), Angiotensin-converting Enzyme (ACE) Inhibitors, β-blockers, Calcium Channel Blockers (CCBs), Diuretics, Fixed-dose Combinations (FDCs), Others and Forecast 2017-2021

Antihypertensive drugs are used to treat hypertension (high blood pressure). Antihypertensive therapy seeks to prevent the complications of high blood pressure, such as stroke and myocardial infarction. There are many classes of antihypertensives, which lower blood pressure by different means. Among the most important and most widely used drugs are thiazide diuretics, calcium channel blockers, ACE inhibitors, angiotensin II receptor antagonists (ARBs), and beta blockers. Patient age, associated clinical conditions and end-organ damage also play a part in determining dosage and type of medication administered. Although such drugs cannot give a radical cure, they can prevent heart failure, kidney failure and acute stroke induced by hypertension and delay the development of atherosclerosis by controlling the blood pressure. The best available evidence favors the thiazide diuretics as the first-line treatment of choice for high blood pressure when drugs are necessary. Although clinical evidence shows calcium channel blockers and thiazide-type diuretics are preferred first-line treatments for most people (from both efficacy and cost points of view), an ACE inhibitor is recommended by NICE in the UK for those under 55 years old. Angiotensin II receptor blockers (ARBs) comprises several leading brands such as Benicar (olmesartan medoxomil), Diovan (valsartan) and Micardis (telmisartan). The ‘others’ category includes endothelin receptor antagonists such as Tracleer, Opsumit (bosentan and macitentan) and Letairis (ambrisentan). All drug classes, except fixed-dose combinations (FDCs), represent sales of monotherapies.

The global antihypertensive drugs market segmentation is based on drug class – angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, β-blockers, calcium channel blockers (CCBs), diuretics, fixed-dose combinations (FDCs), and others.

The global antihypertensive drugs market research report provides market size (Revenue USD Million 2014 to 2021), market share analysis, growth trends and forecast (CAGR%, 2017 to 2021). The global antihypertensive drugs market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global antihypertensive drugs market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries.  The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major players operating in the global antihypertensive drugs market and profiled in this report include Actelion (Nippon Shinyaku), Alvogen, Bayer, Bellerophon Therapeutics, Boehringer Ingelheim, Boryung Pharmaceutical (Stendhal), CJ Healthcare, Daiichi Sankyo, Gilead, Eli Lilly, HanAll Biopharma (Yuhan), Hanmi Pharmaceutical, JW Pharmaceutical, Kitov Pharmaceuticals, Kyowa Hakko Kirin, Lung Biotechnology, Nippon Shinyaku, Novartis, Pfizer, Reata Pharmaceuticals (Kyowa Hakko Kirin), Sanofi, Stendhal, Takeda, United Therapeutics, and Yuhan.

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue USD Million, 2014-2021)
    • Forecast Estimation (Revenue USD Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2025)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Antihypertensive Drugs Market

1. Drug Class
1.1. Angiotensin II Receptor Blockers (ARBs)
1.2. Angiotensin-converting Enzyme (ACE) Inhibitors
1.3. β-blockers
1.4. Calcium Channel Blockers (CCBs)
1.5. Diuretics
1.6. Fixed-dose Combinations (FDCs)
1.7. Others

2. Geography
2.1. North America (U.S., Canada)
2.2. Latin America (Brazil, Mexico, Rest of LA)
2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4. Asia Pacific (Japan, China, India, Rest of APAC
2.5. Rest of the World

3. Company Profiles
3.1. Actelion
3.2. Alvogen
3.3. Bayer
3.4. Bellerophon Therapeutics
3.5. Boehringer Ingelheim
3.6. Boryung Pharmaceutical
3.7. CJ Healthcare
3.8. Daiichi Sankyo
3.9. Gilead
3.10. Eli Lilly
3.11. HanAll Biopharma
3.12. Hanmi Pharmaceutical
3.13. JW Pharmaceutical
3.14. Kitov Pharmaceuticals
3.15. Kyowa Hakko Kirin
3.16. Lung Biotechnology
3.17. Nippon Shinyaku
3.18. Novartis
3.19. Pfizer
3.20. Reata Pharmaceuticals
3.21. Sanofi
3.22. Stendhal
3.23. Takeda
3.24. United Therapeutics
3.25. Yuhan

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*

EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish